- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07940452
A Novel Eye Wash Solution for DED Treatment
A single-center, randomized, participant-masked, placebo-controlled, parallel-group clinical trial designed to evaluate the effectiveness and safety of a novel eye wash solution for the treatment of dry eye disease
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Première phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jiaxu Hong, Department chief
- Numéro de téléphone: 021-64377134
- E-mail: Jiaxu.hong@fdeent.org
Lieux d'étude
-
-
-
Shanghai, Chine
- Fudan Eye, Ear, Nose and Throat Hospital
-
Contact:
- Jiaxu Hong
- Numéro de téléphone: 021-64377134
- E-mail: Jiaxu.hong@fdeent.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age of at least 18 years at the time of signing the informed consent. Provision of written informed consent.
- Tear film break-up time (TBUT) < 10 seconds at both Visit 0 and Visit 1. Ocular Surface Disease Index (OSDI) score ≥ 13 at both Visit 0 and Visit 1. Meibomian gland dysfunction (MGD) score ≥ 3 at Visit 0 or Visit 1.
- Presence of cloudy meibum; or 3 or 4 out of 5 meibomian glands expressible upon eyelid compression; or meibomian gland dropout count ≥ 5 at both Visit 0 and Visit 1.
- Meibomian gland dysfunction scoring: MGD is scored based on the secretion of the central 5 meibomian glands of the lower eyelid. Each gland is scored from 0 to 3 (0 = normal; 1 = thick, yellow-white particles; 2 = paste-like secretion; 3 = no secretion or obstruction), with a total score of 0-15 [12].
- Total corneal fluorescein staining score of 1 < X < 10 (sum of inferior, superior, central, nasal, and temporal regions) according to the National Eye Institute (NEI) grading system at both Visit 0 and Visit 1.
- At both Visit 0 and Visit 1, at least one eye (the same eye) must meet all criteria of items 3, 4, 5, and 6 above.
- Ability and willingness to follow instructions, including participation in all study assessments and visits.
Exclusion Criteria:
- Any clinically significant abnormal findings on slit-lamp examination of the ocular surface at both Visit 0 and Visit 1, or any findings that, in the investigator's judgment, may affect study parameters, which may include ocular trauma, history of ocular trauma, or anterior membrane disease.
- History of Stevens-Johnson syndrome; use of any oral medications known to cause dry eyes (e.g., antihistamines, antidepressants, etc.) within 1 month prior to Visit 0, or expected instability during the study period.
- Active ocular infection; use of any topical antibiotics or topical steroids within 14 days prior to the visit, or potential need for such treatment during the study. Any other eyelid margin treatments, such as meibomian gland expression, systemic antibiotics (e.g., tetracyclines), and oral supplements for eye diseases (e.g., lutein) must remain stable for 14 days prior to the visit and throughout the study period.
- Receipt of LipiFlow, intense pulsed light (IPL), or any other procedures affecting the meibomian glands within 1 month prior to Visit 1.
- Abnormal eyelid structure preventing complete eyelid closure, including entropion, ectropion, or floppy eyelid syndrome, which may cause partial conjunctival exposure or affect eyelid blinking function.
- Placement or removal of a permanent punctal plug within 3 months prior to Visit 1 (or 6 months for dissolvable plugs); or expected placement or removal of a punctal plug at this visit, or expected dissolution of the punctal plug during the study.
- Dry eye caused by scarring, radiation injury, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (commonly seen in vitamin A deficiency).
- Ocular or periocular malignancy.
- Corneal epithelial defect; significant confluent staining or filaments in any part of the cornea.
- History of herpes keratitis.
- Significant ocular allergy symptoms, or expected persistent allergic conditions during the study.
- Diagnosis of active ocular or systemic infection (bacterial, viral, or fungal) accompanied by fever requiring antibiotic treatment.
- Use of contact lenses within 14 days prior to Visit 0, or expected use of contact lenses during the study.
- Any intraocular, corneal, or ocular laser surgery within the past 6 months, or any planned ocular and/or eyelid surgery during the study.
- Employees of the clinical trial site directly involved in the management, administration, or support of this trial, or immediate family members of the same trial site.
- Women who are pregnant, breastfeeding, or planning to become pregnant.
- For women of childbearing potential, refusal to undergo urine pregnancy testing at Visit 0, Visit 1, Visit 2, and Visit 3 (or early termination visit) will be considered a refusal of testing. Non-childbearing potential is defined as permanently sterilized (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal (no menstruation for 12 consecutive months).
- Women of childbearing potential not using effective contraception. Acceptable contraceptive methods include: hormonal oral contraceptives, implantable contraceptive devices, injectable contraceptives, or transdermal contraceptives; mechanical spermicides combined with barrier devices such as a diaphragm or condom; intrauterine devices; or surgical sterilization of the partner. For women who are not sexually active, abstinence may be considered an effective contraceptive method; however, if the subject becomes sexually active during the trial, she must agree to use appropriate contraception as defined above for the remainder of the trial.
- Presence of an uncontrolled systemic disease, in the investigator's judgment. Known allergic reaction to the investigational drug or its components. Significant ocular or periocular rosacea that, in the investigator's judgment, interferes with the trial (e.g., clinically significant facial induration).
- Pterygium in either eye.
- Current participation in an investigational drug or device study, or use of an investigational drug or device within 60 days after Visit 1.
- Non-use of any lipid-based artificial tears (e.g., perfluorohexyloctane ophthalmic solution, etc.), no application of warm compresses, and no use of any eye drops and/or "TrueTear™" device (intranasal tear neurostimulator) within 3 days prior to this visit.
- Presence of systemic immune diseases, such as systemic lupuserythematosus, rheumatoid arthritis, ankylosing spondylitis, Sjögren's syndrome, etc.
- Best-corrected visual acuity ≥ 4.3 in both eyes at Visit 0 and Visit 1 (5-point recording method on the international standard logarithmic visual acuity chart at 5 meters).
- Any condition or circumstance (including language barriers) that, in the investigator's judgment, may place the subject at significant risk, may interfere with study results, or may significantly hinder the subject's participation in the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Bras placebo
|
Saline (NaCl 0.9 %), one drop per eye, 3 times daily (TID) for 28 days. |
|
Expérimental: Eye Wash Solution Arm
|
0.2% DHA eye wash solution, one drop per eye, 3 times daily (TID) for 28 days. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Corneal Fluorescein Staining (CFS) Score
Délai: Baseline (Visit 1) to Day 28 (Visit 3)
|
Change from baseline in corneal fluorescein staining score (total score 0-15) in the study eye. |
Baseline (Visit 1) to Day 28 (Visit 3)
|
|
Change in Ocular Surface Disease Index (OSDI) Score
Délai: Baseline (Visit 1) to Day 28 (Visit 3)
|
Change from baseline in OSDI score (ranging from 0 to 100) to assess dry eye symptoms. |
Baseline (Visit 1) to Day 28 (Visit 3)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- FDEENT-20261111
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .